The peptide ‘aurB’ – derived from a tumour-associated bacteria found in the cancer's microenvironment – has targeted ...

Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancerNew ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, ...

A newly developed therapy inspired by bacteria residing within tumors offers a different way to combat cancer by targeting ...

I n science, whether an anomaly is insignificant or the basis for a promising new field of study can boil down to the ...

Senolytic drug development is transitioning from broad-spectrum agents to precision-targeted and combination strategies that address resistance and improve safety. Studies contrast targeted ...

Researchers showed that small engineered proteins can restore the function of mutated p53 by stabilizing its structure. The ...

A novel peptide therapy shuts down tumor energy production by targeting ATP synthase in mitochondria. The approach decreased tumor growth in preclinical prostate cancer models.

Researchers in Europe have developed miniature antibody-like proteins, called DARPins, that can restore function to multiple p53 mutations, potentially expanding treatment options for various cancers.

Each year, 20 million people are diagnosed with cancer. Various organs can be affected, and cancer types sometimes differ greatly at the cellular and molecular level. In about half of all cases, ...

The protein p53 is mutated in many cancer cells, meaning it can no longer fulfill its protective function against tumor development. A team of scientists from Goethe University Frankfurt, along with ...